<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106907</url>
  </required_header>
  <id_info>
    <org_study_id>FT400-002</org_study_id>
    <nct_id>NCT05106907</nct_id>
  </id_info>
  <brief_title>Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma</brief_title>
  <official_title>An Open and Single Dose-escalation Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD19(ThisCART19) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (r/r B-NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundamenta Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundamenta Therapeutics, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity&#xD;
      of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with relapsed and/or refractory&#xD;
      non-Hodgkin's B cell lymphoma (r/r B-NHL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ThisCART19 cell is a non-gene-editing allogeneic CAR-T cell targeting CD19. This study is&#xD;
      designed to evaluate the safety and clinical activity of ThisCART19 in patients with CD19&#xD;
      positive, relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">October 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related adverse events</measure>
    <time_frame>90 days post infusion</time_frame>
    <description>Incidence and severity of adverse events as assessed by NCI-CTCAE 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Remission Rate (ORR)</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Anti-tumor efficacy by 2014 Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival time</measure>
    <time_frame>3 years</time_frame>
    <description>The interval between administration and disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>3 years</time_frame>
    <description>The interval between administration and death caused by any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>3 years</time_frame>
    <description>EFS is calculated from administration to death, progression of the disease, relapse or gene recurrence, whichever comes first, or last visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>B-cell Malignancy</condition>
  <arm_group>
    <arm_group_label>ThisCART19 cells injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ThisCART19 cells</intervention_name>
    <description>0.2-60 x 10^6 CAR T cells per kg body weight</description>
    <arm_group_label>ThisCART19 cells injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years old, no gender and race limited;&#xD;
&#xD;
          2. Estimated life expectancy &gt; 12 weeks deemed by investigator；&#xD;
&#xD;
          3. CD19 were positive by histopathology and/or cytology diagnosis；&#xD;
&#xD;
          4. Patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL)；&#xD;
&#xD;
          5. Relevant indicators for disease or assessment within 4 weeks after the last treatment;&#xD;
&#xD;
          6. Quality of Life Score (KPS) &gt;50%；&#xD;
&#xD;
          7. Subject has adequate organ function at screening, cardiac ejection fraction ≥ 40%, no&#xD;
             evidence of pericardial effusion as determined by an echocardiogram (ECHO); serum ALT/&#xD;
             AST &lt;3 upper limit of normal (ULN); bilirubin&lt;2.0 mg/dl; serum creatinine ≤1.6 mg/dl&#xD;
             and/or BUN ≤ 1.5 mg/dl;&#xD;
&#xD;
          8. No remission or relapse after hematopoietic stem cell transplantation or autologous&#xD;
             somatic immunotherapy;&#xD;
&#xD;
          9. Unsuitable conditions for stem cell transplantation;&#xD;
&#xD;
         10. Signed informed consent form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women in pregnancy or lactation;&#xD;
&#xD;
          2. In active infection including hepatitis B, hepatitis C, HIV, or other fatal viral and&#xD;
             bacterial infection；&#xD;
&#xD;
          3. The absolute count of nonprimary neutrophil &lt; 0.75×10^9/L or platelet count &lt;&#xD;
             50×10^9/L;&#xD;
&#xD;
          4. Abnormal vital signs and failure to cooperate with examination;&#xD;
&#xD;
          5. Patients with mental or psychological diseases who cannot cooperate with treatment and&#xD;
             efficacy evaluation;&#xD;
&#xD;
          6. Highly allergic constitution or history of severe allergy;&#xD;
&#xD;
          7. Patients with systemic infection or severe local infection requiring anti-infection&#xD;
             treatment;&#xD;
&#xD;
          8. Patients with severe autoimmune diseases;&#xD;
&#xD;
          9. Presence of any other conditions that are unsuitable for this study as judged by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhengyu Li, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Li, Ph.D</last_name>
    <phone>18662604088</phone>
    <email>jli@ctigen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhenyu li</last_name>
      <phone>15950688971</phone>
      <email>lizhenyumd@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

